US Ends HIV Funding in South Africa Over Afrikaner Persecution Claims

US to end funding of South – The United States is set to cut funding for South Africa’s HIV programmes, citing concerns about the government’s alleged targeting of the Afrikaner community. This decision follows claims that South African policies have contributed to the marginalization of white South Africans, particularly those of Afrikaner descent, in the context of the country’s broader efforts to combat the AIDS epidemic. The shift in funding could significantly impact the progress made in reducing HIV infections, which remain a critical public health challenge in the nation.

Background of US Aid to South Africa

Until 2025, the U.S. had been a major contributor to South Africa’s HIV response through the President’s Emergency Fund for Aids Relief (Pepfar), providing an estimated $400 million annually. This support was crucial for expanding access to antiretroviral drugs and strengthening healthcare infrastructure. However, the Trump administration has since initiated a phased reduction of this funding, arguing that South Africa’s policies have not adequately addressed racial disparities. The move has sparked debate over the balance between global health initiatives and domestic political concerns.

Reasons Behind the Funding Cut

President Donald Trump’s administration linked the funding reduction to South Africa’s Black Economic Empowerment policies, which the U.S. claims perpetuate systemic inequality. The executive order signed shortly after Trump’s inauguration accused the government of dismantling equal opportunities for white landowners and fostering racial resentment. These allegations were compounded by South Africa’s international disputes, including its legal action against Israel and its alliance with Iran, which the White House cited as examples of “unjust and immoral practices.”

While the South African government defends its policies as necessary to correct historical inequalities from the apartheid era, critics argue that the focus on racial justice has overshadowed the country’s achievements in HIV treatment. The U.S. also highlighted the Afrikaner community’s vulnerability, stating that South Africa’s HIV programmes had not sufficiently protected this group. This perception has driven the decision to phase out U.S. aid, with the administration emphasizing the need for South Africa to become self-reliant in its health initiatives.

Impact on South Africa’s HIV Response

The phased drawdown of Pepfar funding is expected to create a financial gap, potentially threatening the sustainability of South Africa’s HIV programmes. With over eight million people living with the virus, the country has long relied on international support to maintain its progress. The U.S. has argued that South Africa, as a middle-income nation, can now manage its own healthcare needs. However, South Africa’s health ministry has noted that most antiretroviral drugs are funded separately from the broader HIV budget, underscoring the complexity of the financial landscape.

“South Africa is a middle-income country and is more than capable of supporting its own health programs,” stated a U.S. State Department official confirming the funding cut.

Despite the U.S. decision, the South African government has expressed surprise at the timing of the announcement. Officials noted that the phased reduction was not communicated in advance, raising questions about the coordination between the two nations. The health ministry has reaffirmed its commitment to self-reliance, highlighting its long-standing plans to reduce dependency on foreign aid. Nevertheless, experts warn that the sudden shift could disrupt critical services, particularly in underserved regions where access to HIV treatment is already limited.

Relations between the U.S. and South Africa have been strained in recent years, with Trump’s administration frequently criticizing the country’s policies. The funding cut is part of a broader pattern of diplomatic friction, including the U.S. boycott of the G20 summit hosted by South Africa last November. These tensions have been compounded by the administration’s focus on racial issues, with allegations of a “white genocide” gaining traction in some political circles. The decision to limit aid to South Africa’s HIV programmes reflects a strategic realignment of priorities in U.S.-Africa relations.

Broader Implications for Global Health

The U.S. withdrawal from South Africa’s HIV programmes may have ripple effects on global health initiatives. South Africa has been a key player in the fight against AIDS, with its robust treatment programs serving as a model for other African nations. The funding reduction could also impact the country’s ability to support regional partnerships and share expertise. While the U.S. insists it is fostering self-reliance, the move has drawn criticism from health advocates who argue that continued international support is vital for sustaining progress in the HIV response.

As the phased drawdown of Pepfar funding begins, South Africa faces the challenge of filling the financial gap. The country has already outlined a “bridge plan” to maintain services temporarily, but long-term stability remains uncertain. This development highlights the intersection of health policy and political rhetoric, as the U.S. seeks to align its aid with its narrative of racial justice. For South Africa, the situation underscores the importance of maintaining strong international partnerships in the face of evolving geopolitical dynamics.